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Abstract Using the bnculovlrus/Insect cells system, we have 
expmmed n recombinant protelnase 3 (PR3) -- the neutrophil. 
derived sedne protease autonntlgen I  Wegener's gntnulomatosis 
- -  as  a illyemyiated Intrncellular and membrane-associated 
protein, OIIgosnochnrldes accounted for the difference in 
molecular weights between recombinant (34 kDa) and neutro- 
phiI-PR3 (29 kDn), Whereas rabbit-anti-PR3 igG recognized 
both recombinant and nentrophll-derlved PR3, autoantibodies 
from Wegener patient sent reeognl~l only neutrophil-derived 
PR3, Although ollgosaeeharides were not involved in PR3 
epitope recognition, autoantibodles did not recognize the amino 
acid primary structure of recombinant PR3, Improper disulfide 
bond formation and/or lack of post-translational events in insect 
cells, may affect the conformation of PR3, precluding its 
reactivity with sera f rom WG patients. 
Key words: ANCA; Azurophii granule; Baculovirus; 
Proteinase 3; Wegener 
I. Introduction 
Proteinase 3 (PR3) belongs to the broad family of neutro- 
phil-derived cationic glycoproteins involved in the defense 
against pathogens via the non-oxygen-dependent pa hway 
[I], Described first by Baggiolini a 1978 [2], PR3 is an elas- 
tase-like serine pretense packed in azurophil granules from 
neutrophili¢ polymorphonuclear leukocytes tPMN) [3] which 
degrad~ a variety of extracellular matrix proteins [4] and can 
cause emphysema in hamsters [5]. 
A different starting point of clinical research also led to the 
identification of PR3 as the major, if not sole, target autoanti. 
8an of anti-neutrophil cytoplasmic antibodies (ANCA) asso. 
elated with Wegener's granulomatosis (WG) [6,7]. There is 
mounting evidence that ANCA may play a direct role in the 
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**This work has been partly presented atthe ANCA workshop held 
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Abbrev~tioas: AcMNPV, Autographa t~lifomica mononuclear poly- 
hed~is virus; AG, azurophil granules; ANCA, anti-neutrophil 
cytoplasmic antibody; cANCA, cytoplasmic ANCA; PR3, proteinase 
3: SI9, Spodoptera frugiperda clone 9 cells; WG, Wegener's granulo- 
matosis. 
pathogenesis of ANCA.associated vasculitis and could be 
used as a marker for disease activity [8]. In vitro, ANCA 
can activate neutrophils to produce reactive oxygen species, 
degranulate and damage target cells [9]. Standardized indirect 
immunofluorescence tests to diagnose and monitor patients 
have been developed, based on the typical cytoplasmic pattern 
(cANCA) of alcohol-fixed neutrophils using patient's sera. 
Only antibodies producing this fluorescence pattern turned 
out to be highly specific for WG [10]. 
The cDNA and gene encoding for PR3 have been cloned 
[I !-13] and the molecular genetic similarity between PR3 and 
WG autoantigen has been demonstrated [14]. Several studies 
exploring the nature of antigen recognition of cANCA have 
led to divergent results, some reports provided evidence that 
autoantibodies from WG sera recognized conformational epi- 
topes on PR3 [15], while others described linear epitopes [16] 
similar to surface-exposed regions of PR3. To settle the con- 
troversy and facilitate the mapping of the epitopes of the 
protein, we have expressed PR3 in a baculovirus insect cell 
system which is supposed to carry several of the post-transla- 
tional modifications found in mammalian proteins [17]. 
2. Materials and methods 
2, i, DNA constructs 
For the baculovirus construct, the full length of PR3 eDNA [I I] 
was amplified using the Gene Amp PCR kit (Perkin Elmer Cetus, 
Norwalk, CT) and was cloned using standard techniques [18] into 
the expression plasmid pAcC4 (kindly provided by Dr. R. Stevens, 
Frederick, MA), between the Ncol and Sinai sites, directly behind the 
ATG start codon of the polyhedrin gene which is flanked by wild type 
virus AcMNPV DNA sequences. The complete sequence of this re- 
combinant plasmid esignated pAcC41PR3 was shown to be correct 
by dideoxynucleotide sequencing (Sequenase, version 2.0, US Bio- 
chemical Corp., Cleveland, OH). 
2.2. Transfection a d purification of recombinant virus AcMNPV/PR3 
Spodopteru frugiperda (sfg) cells (ATCC CRL 1711, Rockviile, 
MD) were cultured in TMN-FH medium (Biowhittaker, Walkersville, 
M D), 10% fetal calf serum as described [I 7]. Sf9 were transfected with 
a mixture of 3 pg recombinant plasmid vector (pAcC4/PR3), 1 pg 
linearized wild.type AcMNPV and 20 ~tl cationic liposomes (Invitro- 
gen, San Diego, CA). The recombinant baculovirus (AcMNPWPR3) 
was then cloned and purified as previously described [19]. 
2.3. Indirect immunofluorescence of SJ9 cells 
lmmunofluorescence wasperformed on Sf9 cells grown on cover- 
slips and infected for 2 days with the recombinant virus at a multi- 
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Fig. !. Indirect immunofluorescence of Sf9 cells infected by AcMNPV/PR3. SD cells infected with AcMNPV/PR3 (D, E, F) at 3 days post-in- 
fection, or non-infected SD cells (A, B, C), were viewed by light microscopy (A and D) or examined by fluorescence microscopy (at magnifica- 
tion ×450 in B and E, and magnification ×1000 in C and F). 
plicity of infections of I to !0 pfulmi. Cells were fixed with methanol 
and incubated for ! h with dilutions of polyclonal rabbit anti-PR3 or 
preimmune antibody followed by rhodamine isothiocyanate-conju- 
gated goat IgG anti-rabbit IgG (Jackson ImmunoRe: ,ch Labora- 
tories, Inc., West Grove, PA). 
2.4. Biochemical r~;;a~ysis of ~ecombinant PR3 by Western blot 
AcMNPV/PR3-infected Sf9 cells were harvested at the indicated 
time and washed twice in PBS. Unglycosylated PR3 was produced 
by adding tunicamycin (5 p.g/ml, Calbiochem, La Jolla, CA) to the 
culture medium 1 h post-infection. Sf9 pellets were boiled in reducing 
buffer (104, SDS, 2°4, [5-mercaptoethanol, 5% glycerol) and run on 
12.5% SDS PAGE gel along with prestained molecular weight mar- 
kers (Gibco BRL, Gaithersburg, MD). Proteins were then transferred 
onto nitrocellulose membranes (Schleicher & SchueU, Keene, NH) in 
20°/'0 methanol, 25 mM Tris and 192 mM glycine buffer, pH 8.3, at 
100 V for 2 h. The membrane was incubated for i h with blocking 
solution (Carnation dry milk 504, + 0.0504, Tween 20 in PBS) and in- 
cubated successively with dilutions of polyclonal rabbit anti-PR3 [3] 
and secondary antibody F(ab')2 of donkey IgG anti-rabbit IgG con- 
jugated to alkaline phosphatase (The Jackson Immunoresearch 
Laboratories, West Grove, PA). After washing, the membrane was 
developed using nitroblue tetrazolium and 5.bromo-4-chloro-3-indolyl 
phosphate as substrates (Sigma Chemicals, St Louis, Me). 
Subcellular fractionation was performed on 100x I0 ° AcMNPV/ 
PR3-infected Sf9 cells resuspended in a relaxation buffer (100mMKCI, 
3 mM NaCI, I mM ATP(Na)2, 3.5 mM MgCI2, I0 mM Pipes, pH 7.3) 
and disrupted by nitrogen cavitation for 20 min at 350 psi in a bomb 
at 4°C [20]. Nuclei and unbroken cells were pelleted by centrifugation 
at 500Xg for I0 min at 4°C. The postnuclear supernatant was cen- 
trifuged for 90 min at 100000×g. 
Various solubilization protocols were carried out on Sf9 cells in- 
fected by AcMNPVIPR3 at day 3 post-infection. Sf9 cells were soni- 
cated in a hypotonic Tris buffer (10 mM Tris, pH 7.8, 3 mM MgCI~, 
50 mM KCI) and centrifuged at 100000×g for 45 min. The pellet was 
washed 2 times with 50 mM Tris and submitted to the different ex- 
traction protocols: acid (50mM glycine, pH 2.0, 40 min at 200C), base 
(0.1 M sodium bicarbonate, pH 11.0, 40 min at 200C), salt (2 M 
NaCI, 50 mM NaPe4, pH 7.0, 40 min at 20°C), detergents (Triton- 
XI00 1%, or NP-40 1%, or Chelate 1%, or CHAPS 1%, or Lubrol 
1%, 20 rain at 4°C), organic solvents (100% acetonitrile, 12 h at 4°C), 
denaturing agent (urea 8 M, pH 8, 1 h at 20°C) or strong detergents 
(0.1 and 1% SDS in 50 mM Tris, pH 7.8 for 30 min). The cell extract 
was centrifuged at 100000Xg and pellet and supernatant were ana- 
lyzed for the presence of PR3. All reagents were from Sigma. 
2.5. Purification of PR3 from PMN granules 
Granules of human PMN were isolated [20] and PR3 was purified 
using an aprotinin-Sepharose column [21] followed by Matrex gel 
orange A chromatography [5]. The eluate was then immunoadsorbed 
using a PR3 monoclonal antibody (CLB, Clone 12.8, Amsterdam) 
[221. 
2.6. Glycosylation analysis 
Determination of PMN-purified PR3 glycosylation was performed 
using the Lectin-Link kit (Genzyme, Cambridge, MA) combined with 
chemiluminescent detection. Briefly, purified PMN-derived PR3 (50 
I~g/ml) was first subjected to Western blotting. The membrane was 
then incubated with a panel of biotinylated lectins, including GNA 
( Galanthus nivalis agglutinin), SNA (Sambucus nigra agglutinin), DSA 
(Datura stramonium agglutinin), suitable for identifying 'high man- 
nose', or complex sialylated, or N-acetylglucosamine N-glycan chains, 
respectively. The nitrocellulose membrane was then incubated with 
horseradish peroxidase-conjugated streptavidin (Southern Biotechnol- 
ogy Associates, Inc., Birmingham, AL), and was revealed by ECL 
detection (Amersham, Buckinghamshire, UK), Deglycosylation treat- 
ment was performed as follows: 2 ~tg of PMN.purified PR3 in 50 mM 
Tris, pH 8.0 was first denatured by boiling in 0.5% SDS. The sample 
was diluted with 200 mM sodium phosphate buffer, pH 8.6, 10 mM 
1,10-phenanthroline, and 1.25% NP-40. N-glycanase (Peptide-N-(N- 
acetyl-glucosaminyl) asparagine amidase, EC 3.5.1.52, Genzyme) 
was added at 10 U/ml and the reaction mixture was incubated at 
37°C for 16 h. The samples were then Western blotted. 
2.7. ANCA testing 
High titer sera were obtained from 15 patients uffering from WG. 
The diagnosis was established on the basis of classic symptoms and 
the typical histological findings in biopsy specimens, Sera of these 
132 
patients were selected on the basis of the positivity il~ both indirect 
immunofluorescence performed on alcohol-fixed PMN and ELISA on 
azurophil granule extracts from neutrophiis [22]. Reactivity of Sf9- 
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Fig, 2, Intracellular localization, glycosylation of recombinant PR3 
exprem.~d in Sf9 ceils, PMN-derived azurophil granules containing 
native PR3 were run in the outer lane of each gel for comparison. 
The arrows indicate 34 and 29 kDa, the molecular weights of Sfg. 
and PMN-derived PR3, respectively, Panel A, Sf9 ceils were infected 
with either wild type AcMNPV (WT, lanes I-2) or the recombinant 
baculovirus AcMNPV/PR3 (PR3, lanes 3--4). Sf9 ceils (C) or culture 
medium (M) were collected at 3 days post-infection (0,5× 10 e ceils 
per lane), Panel & Sf9 cells were submitted to nitrogen cavitation 
and an aliquot from each fraction (10 e cells equivalent) was ana- 
lyzed by Western blot: (lane I) total cell lysate after cavitation, 
(lane 2) pellet after low-speed centdfugetion (intact cells + nuclei), 
(lane 3) supernatant after low.speed centfifugation (membrane + or- 
ganites + ¢ytosol), (lane 4) pellet after high-speed centrifugation 
(membranes + organites), (lane 5) supernatant after high-speed cen- 
trifugation (cytosol), Panel C, post-sonication pellets were obtained 
from AcMNPV/PR3-infected S[9 cells in the absence or presence of 
tanicamyein and analyzed by Western blot (20 pg/lane), PR3 pro- 
duced by either untreated (lane I) or tanicamycin-treated AcMNPVl 
PR3-infected Sf9 cells (lane 2) were compared with PR3 from 
PMN-derived azumphil granules (20 pg/lane) (lane 3), Arrows indi- 
cate the same three PR3 isoforms due to different glycosylation 
forms, either in PMN- or in sfg-derived PR3. 
V. Witko-Sarsat e al./FEBS Letters 382 (1996) 130-136 
derived r~.ombinant PR3 with cANCA was successively tested: 
(1) by indirect immunofluorescence performed with dilutions of pa- 
tient serum followed by FITC-conjugated anti-human IgG (Dako, 
Carpinteria, CA); (2) by ELISA on urea and SDS extracts of Sf9 
cells. Briefly, ELISA plates were coated with Sf9 extracts or purified 
azurophii granules olubilized either in 1% Triton-Xl00 or in 8 M 
urea or in 1% SDS (50 pg proteiWmi) in carbonate buffer, pH 9.6. 
After saturation with 1% casein, diluted serum was added and incu- 
bated for I h at 37°C. The second antibody was a biotinylated F(ab°)2 
anti-human IgG (Sigma) detected with an alkaline phosphatase-strep- 
tavidin complex (Amersham, Buckinghamshire, UK) using p-nitro- 
phenyl phosphate (Sigma) as substrate and OD at 405 nm was mea- 
sured [22]; (3) by Western blots performed on 1% SDS Sf9 extracts 
diluted in sample buffer (with or without ~.mercaptoethanol, as in- 
dicated). Western blotting protocol was modified since proteins were 
transferred in 15 mM bicarbonate buffer, pH 10.5 at 100 V for 2 h at 
4°C, Dilutions of sent from WG patients were used as primary anti- 
body and alkaline phosphatase-conjugated anti-human lgG (Sigma) 
was used as secondary antibody. 
3. Results 
3.1. Recombinant PP3 is expressed in SiP cells infi, cted with 
AcMNPVIPP3 
Indirect immunofluorescence showed that no protein react- 
ing with the rabbit polyclonal anti-PR3 IgG was detectable in 
non-infected Sf9 cells, whereas infection of Sf9 cells with 
AcMNPVIPR3 resulted in the expression of the recombinant 
PR3 in Sf9 cells and suggests that PR3 was membrane-asso- 
ciated (Fig. 1) 
3.2. Recombinant PR3 produced by SJ r ) cells is a 34 kDa 
glycosylated membrane-associated protein 
Immunoblot analysis performed with the rabbit polyclonal 
anti-PR3 IgG showed that recombinant PR3 was produced as 
an intra-cellular protein, with a prominent band at 34 kDa, 
and 3 distinct lower bands ranging from 34 to 29 kDa, as 
compared with the native PMN-derived PR3 from azurophil 
granules at 29 kDa. Recombinant PR3 was not secreted as no 
PR3 was detected in the culture medium (Fig. 2A). 
Subcellular fractionation of AcMNPV-infected Sf9 cells fol- 
lowed by immunoblotting analysis revealed that the recon~bi- 
nant PR3 was insoluble and membrane-assc.iated as it w' 
found in the pellet after high-speed centrifugation whereas no 
PR3 was detected in the supernatant (Fig. 2B).Unglycosylated 
recombinant PR3 was produced by AcMNPV/PR3-infected 
Sf9 cells cultured in the presence of tunicamycin, an inhibitor 
of the first step of N-glycosylation. Tunicamycin (5 pg/ml) was 
added 1 h post-infection and Sf9 cells were harvested 3 days 
post-infection. Western blot analysis showed that in the pre- 
sence of tunicamycin recombinant PR3 appears as a single 29 
kDa band, smaller than the PR3 produced in the absence of 
tunicamycin (34 kDa), and similar to the prominent band 
observed with PMN-derived PR3 (Fig. 2C). Oligosaccharides 
accounted for the difference in molecular weight observed 
between recombinant and PMN-derived PR3 and in glycosy- 
lation pattern. 
3.3. Autoantibody recognition of PR3 in WG is 
glycosylation.indepe,dent 
We first investigated the nature of PMN-purified PR3 gly- 
cosylation by lectin probing. Native PR3 reacted with Sambu- 
cus nigra agglutinin (SNA), thus indicating that PR3 bears 
sialic acid (Fig. 3), whereas no reactivity was found with other 
lectins such as GNA or DSA (data not shown). We then 
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4. Discussion 
This is the first report showing the expression of a recom- 
binant PR3, the autoantigen of WG and its biochemical char- 
acterization i  a baculovirus ystem. Although the recombi- 
nant PR3 was not recognized by sera from WG patients, our 
results reveal new information on the nature of the epitope(s) 
recognized by cANCA. 
The recombinant PR3 produced intracellularly by Sf9 cells 
infected with AcMNPV/PR3 can be detected on Western blots 
with specific rabbit polyclonal anti-PR3 IgG. It appears as a 
34kDa protein, which is larger than the 29 kDa native PMN- 
derived PR3 and we further demonstrate hat glycosylation 
accounts for this molecular weight difference. According to 
3.5. Autoantigen activity of Sf9-derived recombinant PR3 
Using indirect immunofluorescence on AcMNPV/PR3-in- 
fected Sf9 cells, in the absence or presence of tunicamycin, 
no difference was found between sera from WG patients 
(n = 7) and from controls (n = 7) (data shown). Using stan- 
dard ELISA techniques [22], we showed that normal control 
serum did not react with neutrophil azurophil granules 
whereas in the case of WG sera, strong reactivity was ob- 
served with azurophil granules extracted with 1% Triton- 
XI00, as well as with 8 M urea or I% SDS, showing that 
3.4. Recombinant PR3 produced by SJ9 cells is highly insoluble 
Immunoblot analysis of the pellet, as well as of the super- 
natant following different solubilization protocols, was per- 
formed and compared to that of non-solubilized Sf9 cell mem- 
branes. Among the 10 different solubilization protocols tested 
to extract PR3 from the cell membrane pellet, only 8 M urea, 
pH 8.0 and 1% SDS, partially solubilized PR3, whereas 0.1% 
SDS did not lead to detectable PR3 in the supernatant. 
Agents commonly used to solubilize peripheral and integral 
membrane proteins (acid, base, high salt concentrations, an- 
ionic, cationic or zwitterionic detergents and solvents) were 
unsuccessful (data not shown). 
treated PMN-purified PR3 with N-glycanase, which releases 
all common classes of Ash-linked oligosaccharides. As ex- 
pected, the lectin SNA did not bind the N.glycanase-treated 
PR3, indicating the removal of the carbohydrate moiety. 
Binding of PMN-purified PK3 to the rabbit polyclonal, mouse 
monoclonal or autoantibodies from WG sera on Western 
blots has essentially the same affinity as the binding of the 
same antibodies to N-glycanase-treated-PMN-purified PR3 
(Fig. 3). It should be noted that, unlike Sf9-derived recombi- 
nar~ PR3, PMN-purified PR3 is not heavily glycosylated. 
different WG sera and gave similar results. 
cANCA reactivity is not impaired by denaturing agents or a 
strong detergent (Fig. 4). In contrast, no specific reactivity 
was observed with Sf9-derived PR3, either in its glycosylated 
or unglycosylated loom. We tested the reactivity of 11 W(3 
sera on PMN-purified PR3 under non-reducing Western blot- 
ting conditions. [3-mercaptoethanol ([3-ME) reduction comple- 
tely abolished cANCA binding for all the sera tested. Simi- 
larly to cANCA, a mouse monoclonal anti-PR3 antibody 
CLB clone 12.8 recognized PR3 only under non-reducing con- 
ditions (Fig. 5). Tested on SDS-extracted Sf9 cells infected 
with AcMMNPVIPR3 in the presence or absence of tunica- 
mycin, the majority of the WG sera tested (9111), as well as 
the mouse monoclonal anti PR3 IgG, did not show any re- 
activity. We did observe, however, with 2 WG sera (2111) as 
well as with one control (!/8), a strong band around 30-31 
kDa, in Sf9 infected with AcMNPV/PR3. In contrast to what 
was observed with the rabbit polyclonal anti-PR3 IgG, this 
band at 30-31 kDa had the same intensity in the presence or 
absence of tunicamycin and was [5.ME-insensitive (Fig. 5). 
Fig. 3. PR3 glycosylation is not involved in cANCA recognition. Glycosylation a alysis was performed on purified PMN-derived PR3 (2 ~g/ 
lane) treated or not with N.glycanase and Western blotted. On the first panel, PR3 (lane I) and N.glycanase-treated PR3 (lane 2) were probed 
with the lectin SNA, which bind~ sialic acid. Transferrin (I00 kDa) was used as a positive control for the lectin SNA (lane 3). On the second 
panel, PR3 (lane I) and N-glycanase-treated PR3 (lane 2) were probed with rabbit polyclonal nti-PR3 IgG. On the third panel, PR3 (lane I) 
and N-glycanase-treated PR3 (lane 2) were probed with mo~t~ monoclonal nti-PR3 IgG. On the fourth panel, PR3 (lane I) and N-glycanase- 
treated PR3 (lane 2) were probed with serum from WG pa~;ent umber I. This representative experiment was performed five times with five 
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Fig. 4. ELISA comparing the binding of sera either from control or from Wegener's patients with PMN-derived PR3 or recombinant PR3 pro- 
dueed in AcMNPV/PR3-infected Sf9 cells. Sf9 cells infected either with wild type AcMNPV, or AcMNPV/PR3 in the presence or absence of 
tunieamycin were sonicated, centrifuged toobtair, the membrane-associated fraction containing recombinant PR3. sfg-derived membrane frac- 
tions or azurophil granules were extracted with different protocols including 8 M urea or !% SDS for both azurophii granules and Sf9 cells 
and I% Triton-Xi00 for azurophii granules. These extracts were coated in parallel on ELISA plates and sera from either a control subject 
(panel A) or a WG patient (panel B) were tested. This representative experiment, including a serum from a control subject and from a WG pa- 
tient, was performed five times and gave similar esults. 
our study, native PMN-derived PR3 was weakly glycosylated, 
and appeared to display a complex oligosaccharide-like struc- 
ture, with terminal sialic acid residues. It has been suggested 
that Sf9 cells lack detectable N-acetyl-glucosaminyl-, galacto- 
syl-, and sialyltransferase activities, and would not allow the 
addition of terminal sugars normally found in the complex 
oligosac~harides of vertebrate cells [23]. Detailed and com- 
plete structural studies of ofigosa¢charides of our recombinant 
PR3, as well as protein sequencing, were hampered by its 
insolubility and failure to immunopr~ipitate (data not 
shown). The conditions used to solubilize intracellular PR3 
(1% SDS or 8 M urea) suggest hat this protein could be 
part of an aggregate or complexed with other structures. 
This insolubility, which precludes imple purification proto- 
cols, renders obligatory a denaturation step with 8 M urea 
or guanidinium chloride followed by renaturation. Using 
small synthetic peptides as substrates [24], we failed to demon- 
strate a reproducible serine proteinase activity in urea-solubi- 
lized Sf9 membranes. 
In PMN, PR3 is present in azurophil granules, which are 
cellular or~nites pecific to cells from the myeloid lineage and 
the intracellular targeting of PR3, and of other proteins from 
azurophil granules, has not been elucidated but does not ap- 
pear to be similar to the targeting of iysosomal enzymes via 
the mannose-phosphate receptor [25]. A likely explanation is
that Sf9 cells are devoid of the specific enzymatic equipment 
as well as specific ellular organites that are required for prop- 
er folding and/or processing and/or targeting of PR3. Indeed, 
the similarity between the apparent molecular weight of N- 
glycanase-treated PMN-purified PR3 and unglycosylated Sf9- 
derived PR3 may suggest that, as described for other proteins 
produced in a baculovirus ystem, the signal sequence has, 
most likely, been processed. We evaluate two other constructs 
that code for different form: of PR3. Since the post-transla- 
tional processing of PR3 involves at least three proteolytic 
steps to form the mature nzyme, we cotlstructed a recombi- 
nant baculovirus coding for the mature protein, without signal 
sequence and propeptide. No recombinant PR3 was produced 
(data not shown). As it has been described that elastase or 
cathepsin G undergo a carboxy terminal processing, we e~:- 
pressed a 12 amino acid-truncated recombinant PR3. The 
truncated protein was still membrane associated (data not 
shown). It has to be noted that azurocidin, another azurophil 
granule-derived protein which shares 45% sequence homology 
with PR3, was successfully expressed as a secreted and a fully 
biologically active recombinant antibiotic protein in the same 
baculovirus ystem. Interestingly, the type of glycosylation --
high mannose -- was similar in PMN- and Sf9-derived PR3 
(Almeida et al., manuscript submitted for publication). Our 
present results uggest that production of recombinant PR3 in 
a baculovirus ystem is more complex 
The second set of findings provides new insights into the 
nature of the epitopes recognized by WG autoantibodies and 
supports the concept of conformation-dependent bi ding of 
autoantibodies to PR3. We have shown by ELISA that PMN- 
derived PR3 antigenicity isconserved in 8 M urea or 1% SDS, 
thus demonstrating that the conformational epitopes are 
maintained by disulfide bonds even in denaturing conditions. 
Moreover, we tested WG sera using Western blot techniques 
after boiling the samples in 1% SDS but in the absence of 13- 
ME and showed that WG sera did not recognize recombinant 
PR3, either in its glycosylated or unglycosylated form. Inter- 
estingly, the mouse monoclonal anti-PR3 had the same recog- 
nition pattern whereas the rabbit polyclonal anti-PR3 anti- 
body recognized both PMN- and Sf9-derived PR3, 
regardless of its glycosylation state, in the absence or presence 
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Fig. 5. Reactivity of recombinant PR3 with Wegener's era tested by Western blot analysis. PMN-derived azurophil granule~ and the post-soni- 
cation pellet from AcMNPV/PR3-infected Sf9 cells were extracted with !% SDS and the solubilized fractions were dissolved in sample buffer, 
under non-reducing (in the absence of ~-ME, on the upper set of blots) or reducing conditions (in the presence of I3-ME, on the lower set of 
blots). Samples were run on 12.5"/o SDS-PAGE gel (20 ~tg/lane) and analyzed by Western blot. All samples including PMN-PR3, wild type 
AeMNPV- or AcMNPV/PR3-infected Sf9 cells in the presence or absence of tunicamycin, were incubated either with rabbit polyclonal anti- 
PR3 lgG, or mouse monoclonal anti-PR3 IgG, or human sera from a normal subject (N) or WG patients: WG1 was representative of the 
group of 9 out of 11 higb-titer WG sera which did not show any cross reactivity with AcMNPV/PR3-infected cells, and WG2 was representa- 
tive of the three sera which showed a non-specific cross reactivity with a 30-31 kDa protein. Relative molecular weights of prestained markers 
are shown at the left. Results are representative of 5 experiments. 
of reducing agent. It should be noted that this polycional 
rabbit antibody has been raised against PR3 purified by 
HPLC partially denatured by acid treatment [3]. The fact 
that mouse monoclonal anti-PR3 and the WG sera did not 
recognize Sf9-derived PR3 indicates that an obligate biochem- 
ical feature, present in PMN-derived PR3, is lacking in the 
recombinant PR3. 
As shown by the PR3 eDNA sequence, 8 cysteine residues 
are present, allowing the possible formation of four intramo- 
lecular disulfide bonds. Recombinant PR3, produced either in 
an in vitro translation system or in bacteria [15], failed to be 
recognized by autoantibodies from Wegener's era. The lack 
of reactivity of recombinant fusion protein could be attributed 
to an incorrect folding due to the highly reductive intracellular 
environment of E. coil. This problem should have been circum- 
vented by expressing recombinant PR3 in a baculovirus ys- 
tem, as disulfide bonds are usually formed (as observed for 
azurocidiri and other autoantigens [26]). However, the absence 
of serine t, roteinase activity and ANCA reactivity strongly 
suggests that recombinant PR3 has aberrant folding. Our ana- 
lysis of the importance of the carbohydrate moieties in the 
binding of PR3 to Wegener's autoantibodies clearly shows 
that autoantibody recognition of PR3 epitope(s) is mainly 
oligosaccharide-independent in PMN-derived PR3, which al- 
ready has a proper folding. Glycosylation, however, may also 
be involved in the folding process of PR3 as suggested by 
other reports showing that the N-linked oligosaccharides 
and their processing are critical for proper glycoprotein fold- 
ing and assembly [27]. 
In conclusion, sfg-derived PR3 is not recognized by cAN- 
CA, thus suggesting that its lacks an obligate biochemical 
feature required for ANCA recognition. Disulfide bond for- 
mation and/or post-translational events may affect the confor- 
mation of the molecule to such a great extent hat the absence 
of such a modification, which may occur in a restricted num- 
ber of cell types, would preclude the reactivity of the protein 
with the majority of autoantibodiea found in sera from WG 
patients. 
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